The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

Atogepant 60 mg vs rimegepant and galcanezumab for episodic migraine prevention has superior efficacy, with comparable safety ...

Atogepant 60 mg once daily leads to meaningful weight loss in patients with overweight or obesity receiving preventive ...

What if we told you that scientists are currently testing a new weight-loss drug that’s similar to Ozempic but sans the scary ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...